Evergreening of patents is done by

1. Evolution of Intellectual Property Rights in India (basic)

Welcome to your first step in understanding the world of Intellectual Property Rights (IPR) in India. To understand how we handle cutting-edge biopharmaceuticals today, we must first look at how our laws evolved to balance two competing needs: rewarding innovation and ensuring public affordability.

For decades, the bedrock of our system was the Indian Patent Act of 1970. Originally, this law was designed to help India become self-sufficient in medicines. It did this by only allowing process patents for food and drugs, rather than product patents. This meant a company could patent the specific method of making a drug, but not the drug itself. This allowed Indian generic companies to develop clever new ways to manufacture the same medicine at a fraction of the cost Indian Economy, Vivek Singh, International Organizations, p.389.

However, as India integrated into the global economy, we joined the World Trade Organization (WTO) and committed to the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights). This required a massive shift. Between 1995 and 2005, India amended its laws to align with global standards. The most significant change came with the Patents (Amendment) Act of 2005, which finally introduced product patents for pharmaceuticals, meaning the chemical substance itself could now be protected for 20 years Indian Economy, Vivek Singh, International Organizations, p.388.

To prevent these stronger protections from making medicines unreachable for the poor, India built in unique safeguards. Two of the most important are:

• Section 3(d): This prevents "Evergreening," where companies try to extend their 20-year monopoly by making minor, insignificant changes to a drug. To get a new patent, they must prove the new version has significantly better "therapeutic efficacy" Indian Economy, Vivek Singh, International Organizations, p.386.
• Compulsory Licensing (Section 84): The government can allow third parties to manufacture a patented drug without the owner's consent under specific conditions, such as if the drug is unaffordable or in short supply Indian Economy, Vivek Singh, International Organizations, p.388.

Sources: Indian Economy, Vivek Singh, International Organizations, p.386; Indian Economy, Vivek Singh, International Organizations, p.388; Indian Economy, Vivek Singh, International Organizations, p.389; Indian Economy, Vivek Singh, International Organizations, p.390

2. The TRIPS Agreement and Global Standards (basic)

The TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement, established during the Uruguay Round of trade negotiations, is the most comprehensive multilateral agreement on intellectual property (IP). Administered by the WTO (World Trade Organization), it sets down minimum standards for IP regulation that apply to all member nations. Before TRIPS, global IP standards were fragmented; TRIPS essentially 'globalized' IP protection by requiring members to recognize rights like patents, copyrights, and trademarks from other member nations Indian Economy, Vivek Singh, International Organizations, p.388-389. This created a uniform playing field, ensuring that a patent granted in one country receives protection in another, though the WTO does allow for 'reasonable restrictions' to protect public interest Indian Economy, Vivek Singh, International Organizations, p.389. For the pharmaceutical sector, the shift to TRIPS compliance was a watershed moment. Prior to 2005, India followed the Patents Act of 1970, which only allowed 'Process Patents' for drugs. This meant Indian companies could reverse-engineer a drug and manufacture it using a different method, leading to a thriving generic industry Geography of India, Majid Husain, Industries, p.60. However, to become TRIPS-compliant, India amended its laws in 2002 and 2005 to introduce 'Product Patents' for pharmaceuticals Indian Economy, Vivek Singh, International Organizations, p.388. This meant that the chemical substance itself was now protected, preventing others from making the same drug even via a different process. While TRIPS mandates protection, it also opened the door to a strategy called 'Evergreening.' This occurs when companies file secondary patents for minor modifications—such as a new formulation or a 'new use' for an existing drug—to extend their 20-year monopoly beyond the original patent's expiry. To balance innovation with affordable healthcare, India's Section 3(d) of the Patents Act serves as a safeguard. It stipulates that a mere discovery of a new form or use of a known substance is not patentable unless it results in significantly enhanced therapeutic efficacy Indian Economy, Vivek Singh, International Organizations, p.386.

Feature	Process Patent (Pre-2005)	Product Patent (Post-2005)
What is protected?	The specific method or process of manufacturing.	The actual chemical substance or drug molecule.
Reverse Engineering	Allowed (if a different process was used).	Strictly prohibited.
Impact on Generics	High availability of low-cost generic drugs.	Restricted; generics enter only after patent expiry.

Sources: Indian Economy, Vivek Singh, International Organizations, p.378, 386, 388, 389; Geography of India, Majid Husain, Industries, p.60

3. Generic Drugs and India's Pharma Role (intermediate)

To understand India's dominance in the global pharmaceutical landscape, we must first define the Generic Drug. A generic drug is a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, and performance characteristics Indian Economy, International Organizations, p.389. While they contain the same active ingredients, they are significantly more affordable because generic manufacturers do not have to repeat the expensive clinical trials that the original developer conducted.

India has rightfully earned the title of the 'Pharmacy of the World'. Currently, the country ranks third globally in terms of production volume, accounting for roughly 10% of the global share Geography of India, Industries, p.60. This massive scale allows India to export affordable life-saving medicines to the USA, Europe, and Japan. To maintain this balance between innovation and affordability, the Indian government uses the National Pharmaceutical Pricing Authority (NPPA) to fix and revise prices, ensuring that essential medicines remain within reach of the common man Geography of India, Industries, p.63.

Feature	Brand-Name Drug	Generic Drug
Active Ingredient	Identical	Identical
Price	High (to recover R&D costs)	Low (competition-driven)
Market Entry	First to market	After patent expiry (usually 20 years)

A critical challenge in the generic industry is 'Evergreening'. This is a strategy where pharmaceutical companies file for 'secondary patents' on minor changes to a drug (like a new formulation or a slightly different use) just as the original patent is about to expire. This creates a 'patent thicket' to prevent generic entry. India famously counters this through Section 3(d) of the Patent Act 1970. This provision stipulates that mere discovery of a new form of a known substance—which does not result in the enhancement of the known efficacy of that substance—is not patentable Indian Economy, International Organizations, p.386. This ensures that the 20-year monopoly isn't extended indefinitely through trivial tweaks.

Sources: Indian Economy, International Organizations, p.389; Geography of India, Industries, p.60; Geography of India, Industries, p.63; Indian Economy, International Organizations, p.386

4. Compulsory Licensing and Public Interest (intermediate)

In the world of biopharmaceuticals, patents grant a 20-year monopoly to companies to recoup their massive research and development (R&D) costs. However, this monopoly can sometimes lead to 'market failure' where life-saving drugs are priced beyond the reach of the common man. To prevent this, the legal framework provides a 'safety valve' known as Compulsory Licensing (CL). Essentially, CL is an authorization granted by the government to a third party to produce a patented product without the patent owner's consent, ensuring that public interest prevails over private profit Indian Economy, Vivek Singh, Chapter 13, p.389.

India’s journey with Compulsory Licensing is deeply rooted in international law. While the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement established global patent standards, it gave member countries the flexibility to grant CLs to protect public health. India amended its Patents Act, 1970 in 2002 and 2005 to become TRIPS-compliant while retaining these vital public interest safeguards Indian Economy, Vivek Singh, Chapter 13, p.388. It is important to note that a Compulsory License is not 'theft'; the manufacturer who receives the license must still pay a royalty to the original patent holder, the rate of which is determined by the government Indian Economy, Vivek Singh, Chapter 13, p.389.

Under the Indian Patents Act, there are two primary routes through which a Compulsory License can be triggered:

Feature	Section 84 (Market-Driven)	Section 92 (Government-Driven)
Trigger	A manufacturer approaches the government after failing to get a voluntary license from the owner.	The Government issues a notification due to a crisis.
Grounds	Drug is unavailable, unaffordable, or the patent is not being 'worked' (manufactured) in India.	National emergency, pandemic (like Covid-19), or circumstances of extreme urgency.

Sources: Indian Economy, Vivek Singh, International Organizations, p.388; Indian Economy, Vivek Singh, International Organizations, p.389

5. TRIPS Plus and Data Exclusivity Debates (exam-level)

To understand the current global debate on medicine affordability, we must first look at the baseline: the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights). Established under the WTO in 1995, TRIPS set the minimum standards for IP protection, such as a mandatory 20-year patent term Indian Economy, Vivek Singh (7th ed. 2023-24), Chapter 13, p. 386. For India, this meant a massive shift in 2005, moving from only protecting the process of making a drug to protecting the product itself Indian Economy, Vivek Singh (7th ed. 2023-24), Chapter 13, p. 388. However, developed nations often push for 'TRIPS Plus' provisions through bilateral Free Trade Agreements (FTAs) Indian Economy, Vivek Singh (7th ed. 2023-24), Chapter 13, p. 377. These provisions go beyond WTO requirements, aiming to extend the monopoly of big pharmaceutical companies.

One of the most controversial 'TRIPS Plus' demands is Data Exclusivity (DE). Usually, when a generic company wants to launch a cheaper version of a drug after a patent expires, they don't re-run expensive clinical trials; they simply prove their drug is 'bio-equivalent' to the original. Data Exclusivity, however, bars drug regulators from using the innovator's trial data to approve generics for a set period (e.g., 5-10 years). This creates a non-patent barrier: even if a drug is off-patent, a generic firm cannot get market approval unless they spend millions to repeat the trials, which effectively keeps drug prices high and delays the entry of affordable medicine.

Another major point of friction is Evergreening. This is a strategy where companies file secondary patents for minor changes—like a new dosage form or a slightly different formulation—just as the original patent is about to expire Indian Economy, Vivek Singh (7th ed. 2023-24), Chapter 13, p. 386. India famously resists this through Section 3(d) of the Patents Act, which states that a 'new form' of a known substance is not patentable unless it shows significantly enhanced therapeutic efficacy. This legal safeguard prevents the creation of 'patent thickets' that block competition.

Feature	TRIPS (Standard)	TRIPS Plus (Proposed)
Patent Term	Minimum 20 years.	Extensions beyond 20 years (Patent Term Restoration).
Trial Data	Requires protection against 'unfair commercial use'.	Mandatory Data Exclusivity (total ban on using data).
New Uses	Flexible; India restricts under Section 3(d).	Mandatory patents for 'new uses' of old drugs.

Sources: Indian Economy, Vivek Singh (7th ed. 2023-24), Chapter 13: International Organizations, p.377, 386, 388

6. Section 3(d): The Safeguard Against Frivolous Patents (exam-level)

To understand Section 3(d), we must first understand the strategy it aims to defeat: Evergreening. In the pharmaceutical world, a patent grants a 20-year monopoly. As this period nears its end, companies often try to extend their exclusivity by filing 'secondary patents' for minor tweaks—such as a new salt form, a different formulation, or a new delivery method—that don't actually improve how well the drug works. This creates a patent thicket, delaying the entry of affordable generic medicines. Indian Economy, Vivek Singh (7th ed.), Chapter 13, p. 386.

India’s transition to a modern patent regime was pivotal. To comply with the TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement, India amended its Patents Act in 2005 to allow Product Patents for drugs. Indian Economy, Vivek Singh (7th ed.), Chapter 13, p. 388. However, lawmakers were wary that big pharma might abuse this to maintain permanent monopolies. Thus, Section 3(d) was retained and strengthened as a unique 'public health safeguard.'

The core of Section 3(d) is a strict standard of Therapeutic Efficacy. It stipulates that the mere discovery of a new form of a known substance is not patentable unless it results in the enhancement of the known efficacy of that substance. Simply making a drug more stable or easier to store is usually not enough; it must show a significant improvement in its medicinal effect on the body. This prevents 'frivolous patents' and ensures that India remains the 'pharmacy of the world' by allowing generic versions of drugs to be produced once the original 20-year breakthrough patent expires.

Concept	Definition	Purpose
Evergreening	Extending patent life through minor, non-substantive changes.	Maintain market monopoly and high prices.
Section 3(d)	Legal provision requiring proof of enhanced therapeutic efficacy.	Prevent frivolous patents and promote generic competition.

Sources: Indian Economy, Vivek Singh (7th ed.), Chapter 13: International Organizations, p.386; Indian Economy, Vivek Singh (7th ed.), Chapter 13: International Organizations, p.388

7. Understanding Evergreening Strategies (exam-level)

In the world of Intellectual Property Rights (IPR), a patent is essentially a 'grand bargain' between an inventor and the state: the inventor discloses the details of their invention to the public in exchange for a 20-year monopoly to exclusively manufacture and sell it Indian Economy, Nitin Singhania (ed 2nd 2021-22), International Economic Institutions, p.543. However, as this 20-year term nears its end, pharmaceutical companies often employ a strategy known as Evergreening. This refers to the practice of filing 'secondary patents' on minor modifications of an existing drug—such as a new delivery method, a different dosage form, or a slightly altered chemical formulation—to extend market exclusivity without necessarily offering a breakthrough in treatment Indian Economy, Vivek Singh (7th ed. 2023-24), International Organizations, p.386.

While these tweaks might seem like innovation, they often create what experts call a 'patent thicket'—a dense web of overlapping intellectual property rights that makes it nearly impossible for generic drug manufacturers to enter the market. This is particularly significant in India, which is a global hub for affordable medicine, ranking third in the world by volume of production Geography of India, Majid Husain (9th ed.), Industries, p.60. To protect public health, India’s legal framework includes a unique safeguard: Section 3(d) of the Patent Act 1970. This provision explicitly states that a new form of a known substance is only patentable if it shows significantly enhanced therapeutic efficacy. By preventing patents on minor 'iterations' that offer no real medical benefit, India ensures that life-saving drugs remain affordable once the original patent expires.

Feature	Standard Innovation	Evergreening Strategy
Primary Goal	Discovery of a new molecular entity.	Extension of a dying patent's lifespan.
Nature of Change	Significant scientific breakthrough.	Minor reformulations or new 'uses'.
Market Impact	Drives progress and new treatments.	Delays the entry of cheaper generics.
India's Stance	Fully patentable (20 years).	Restricted by Section 3(d).

Sources: Indian Economy, Vivek Singh (7th ed. 2023-24), International Organizations, p.386; Indian Economy, Nitin Singhania (ed 2nd 2021-22), International Economic Institutions, p.543; Geography of India, Majid Husain (9th ed.), Industries, p.60

8. Solving the Original PYQ (exam-level)

In your recent lessons on Intellectual Property Rights (IPR), you explored how patents grant a fixed 20-year monopoly to reward innovation. The concept of evergreening is a strategic attempt by companies—primarily in the pharmaceutical sector—to bypass this expiration date. As you learned from Indian Economy by Vivek Singh, evergreening involves making minor, incremental modifications to an existing drug to secure a fresh patent cycle. This question tests your ability to identify the specific mechanism—citing a "new use" or a "new form"—that allows a company to maintain market dominance and delay the entry of affordable generic drugs long after the original chemical compound should have entered the public domain.

To arrive at the correct answer, (A) citing another use of the same product, you must think like a patent lawyer looking for a loophole. If the primary patent on a molecule is expiring, claiming it can treat a different medical condition (a new use) serves as the basis for a secondary patent. This effectively "evergreens" the monopoly. UPSC uses Options (B) and (D) as distractors; while a process patent (B) or a new product (D) involves intellectual property, they do not represent the core tactic of extending the life of the original product. Option (C) is a common trap because, in most jurisdictions including India, you cannot simply "apply for an extension" of the 20-year term; you must present a technically new invention. Remember that Section 3(d) of the Indian Patent Act specifically restricts this practice by requiring proof of significantly enhanced therapeutic efficacy, a point often debated in WTO-TRIPS forums.